AVBP vs AVTX

ArriVent BioPharma, Inc. vs Avalo Therapeutics, Inc. — Valuation Comparison 2026

AVBP

Biotechnology
ArriVent BioPharma, Inc.
Quality
3.6
out of 10
Value Trap
12
SAFE
Price
$26.97
Last close
Models
7/13
Active
VS

AVTX

Biotechnology
Avalo Therapeutics, Inc.
Quality
4.7
out of 10
Value Trap
49
WARN
Price
$16.13
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType AVBP Fair ValueAVBP Upside AVTX Fair ValueAVTX Upside
Bayesian DCF Intrinsic $7.90 -70.7% $4.59 -71.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.59 -98.0% $0.69 -95.7%
Dynamic NAV Asset-Based $6.38 -76.3% $1.11 -93.1%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for AVBP vs AVTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AVBP vs AVTX — Which Stock Is More Undervalued?

AVTX scores higher with a 4.7/10 quality rating vs AVBP's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing ArriVent BioPharma, Inc. (AVBP) and Avalo Therapeutics, Inc. (AVTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AVBP currently trades at $26.97 with a QOC of 3.6/10, while AVTX trades at $16.13 with a QOC of 4.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).